1.Effects of Bushenxingnao Prescription on Cerebral Neurocyte Apoptosis of Experimental Vascular Dementia Rats
Pan ZHENG ; Yinman FENG ; Hong ZHENG
Chinese Journal of Information on Traditional Chinese Medicine 2006;0(12):-
Objective To study the pathology mechanism of vascular dementia(VD)rats and study the effect of Bushenxingnao(BSXN)prescription on cerebral neurocyte apoptosis.Method Experimental VD model rats were caused by clipping two side of total artery in neck repeatedly and to examine cerebral neurocyte apoptosis with TUNEL.Results Both the high and low dose BSXN abated excitatory toxic infury and inhibit neurocyte apoptosis after ischemia-refusion.Conclusion BSXN prescription can repress cerebral neurocyte apoptosis,to abate its excitatory nerotoxicity,to protect cerebral neurocyte,which may be one of the mechanisms of to treating the lesion.
2.Clinicopathologic study on gastric mini-cancer
Hong SHEN ; Wensheng PAN ; Ying YUAN ; Shu ZHENG
Chinese Journal of General Surgery 2009;24(4):269-272
objective To investigate the clinicopathological features of mini-cancer of the stomach. Method In this study,out of 296 early gastric cancer cases there were 34 cases of early gastric cancer in which tumor diameter was≤10 mm,among those there were 5 cases with tumor size≤2 mm and 29 cases of the size 2~10 mm. Result Mini-cancer accunted for 2% of all early gastric cancers in this series:All these mini-cancers were of intramucosal cancer(100%),while that took up to 45%in control group in which tumors were between≥2 mm and≤10 mm:Tumors were high or moderately differentiated pathologically in 100%of mini-cancers and 55%in control group.None of mini-cancer patients had lymph node metastasis,however,1 of 29 patients in control group had lymph node metastasis.Both groups had no blood vessel and lymphatic vessel invasion:The differentiation concordance rate between superficial lesions and invasive fronts in mini-cancer was 100%,higher than 86%in control group. Conclusion Gastric mini-cancer is usually of high differentiation,low tumor invasion and low rate of lympy node metastasis than control group.Endoscopic therapy is applicable for most gastric mini-cancers.
3.Retransplantation of HCC patients with or without HCC recurrence
Haiming ZHANG ; Hong ZHENG ; Yonglin DENG ; Cheng PAN ; Zhijun ZHU
Chinese Journal of Organ Transplantation 2013;34(7):407-410
Objective To explore the efficacy of liver retransplantation for hepatocellular carcinoma (HCC) patients with or without HCC recurrence.Method 131 cases of retransplantation performed between 2003 and 2012 were analyzed retrospectively.Their first and second liver transplantations were both performed in our hospital.Diagnoses of their primary diseases before transplantations were confirmed pathologically after the first transplantation.Patients were divided into two groups in terms of benign causes and HCC.Results Sixty cases were fallen into benign disease group and 65 cases into HCC group.The proportions of main causes of retransplantation were similar between two groups.The graft survival rate of early retransplantation (retransplantation performed within 30 days after the first transplantation) and late retransplantation (retransplantation performed beyond 30 days after the first transplantation) was calculated and compared respectively due a great difference in survival rate between the two phrases.The deaths of HCC patients with HCC recurrence before retransplantation were more than those without HCC recurrence (P<0.01) and benign disease group.The 5-year cumulated survival rate was close between HCC patients without recurrence before retransplantation (51.0%) and benign disease group (51.8%).Conclusion The retransplantation after HCC recurrence has an unacceptable prognosis.The survival rate was similar between patients without HCC recurrence and patients with benign diseases.HCC patients without recurrence should not be restrained from retransplantation just for the HCC history.
4.Clinical application of Cylex ImmuKnow assay in patients with renal dysfunction after liver transplantation
Weiping ZHENG ; Daihong LI ; Yihe LIU ; Hong ZHENG ; Yonglin DENG ; Cheng PAN ; Zhongyang SHEN
Chinese Journal of Organ Transplantation 2013;34(11):661-665
Objective To assess the clinical application of Cylex ImmuKnow assay in patients with renal dysfunction after liver transplantation for individualized immunosuppressive therapy.Method Twenty adult patients undergoing liver transplant between January 2009 and December 2011 received regular ImmuKnow assay monitoring combined with determination of serum tacrolimus trough concentration to guide immunosuppressive regimens,all of whom showed sustained renal dysfunction 6 months after transplant with normal and stable liver function.Clinical data were collected to observe the changes of renal function in those patients after treatment.Results The recipients were followedup for 15-54 months,received ImmuKnow assay 61 times and the results fluctuated 33-943 μg/L [median 282 μg/L,interquartile range (IQR) 267 μg/L].After ImmuKnow monitoring,serum creatinine level in patients was decreased significantly from median 151.8 μmol/L with IQR 44.9 μmol/L to median 114.9 μmol/L with IQR 35.3 μmol/L (Z =-3.845,P =0.000),and estimated glomerular filtration rate (eGFR) was increased significantly from median 0.746 mL/s with IQR 0.025 mL/s to median 1.005 mL/s with IQR 0.454 mL/s (Z =-3.771,P =0.000).ImmuKnow results showed a linear correlation with the white blood cell count in patients (Spearman correlation coefficient r =0.429,P =0.001),but no linear correlation with the patients' age,primary disease before transplantation,postoperative time,serum tacrolimus trough concentration,lymphocyte count,CD3+ T lymphocyte count,CD4+ T lymphocyte count or CD4+/CD8+ T lymphocyte ratio (P> 0.05).Conclusion Cylex IrmmuKnow assay can be applied in patients with renal dysfunction after liver transplantation for individualized immunosuppressive therapy monitoring,which is of certain clinical value.
5.Molecular and histologic characteristics of secondary imatinib-resistant gastrointestinal stromal tumors.
Song ZHENG ; Jing JIA ; Yue-long PAN ; De-you TAO ; Hong-sheng LU
Chinese Journal of Pathology 2013;42(1):42-43
Aged
;
Antineoplastic Agents
;
therapeutic use
;
Benzamides
;
therapeutic use
;
Drug Resistance, Neoplasm
;
Exons
;
Gastrectomy
;
methods
;
Gastrointestinal Neoplasms
;
drug therapy
;
metabolism
;
pathology
;
surgery
;
Gastrointestinal Stromal Tumors
;
drug therapy
;
metabolism
;
pathology
;
surgery
;
Humans
;
Imatinib Mesylate
;
Liver Neoplasms
;
drug therapy
;
secondary
;
Male
;
Piperazines
;
therapeutic use
;
Point Mutation
;
Proto-Oncogene Proteins c-kit
;
genetics
;
metabolism
;
Pyrimidines
;
therapeutic use
6.Studies on chemical constituents of Zhuang medicine Excoecaria venenata and their cytotoxic activity.
De-sheng NING ; Xiao-xu YAN ; Si-si HUANG ; Ling CHENG ; Juan LI ; Zheng-hong PAN
China Journal of Chinese Materia Medica 2015;40(4):686-690
Fourteen compounds were isolated from 95% ethanol extract by silica gel, MCI, and ODS column chromatography. These compounds were respectively identified as quercetin (1), kaempferol (2), (+)-catechin (3), fraxin (4), protocatechuic acid (5), gallic acid (6), methyl gallate (7), ethyl gallate (8), apocynol A (9), baccatin (10), cerevisterol (11), ellagic acid (12), 3, 3',4'-tri-0-methylellagic acid(13) and N-benzoyl-L-phenylalaninyl-N-benzoyl-L-phenylalaninate(14) by analyzing their spectral data and comparing with the previously reported literatures. Except for gallic acid (6), all other compounds were isolated from this plant for the first time. Compounds 1, 2 and 6 showed moderate anti-proliferation activities on tumor cells.
Cell Line, Tumor
;
Cell Proliferation
;
drug effects
;
Cell Survival
;
drug effects
;
Drugs, Chinese Herbal
;
chemistry
;
toxicity
;
Euphorbiaceae
;
chemistry
;
Humans
;
Plants, Medicinal
;
chemistry
;
Spectrometry, Mass, Electrospray Ionization
7.Clinical study on treatment of chronic hepatitis B by kurarinone combined with interferon alpha-1b.
Zheng-Shun PAN ; Qiong-Hua YU ; Hong YAN ; Yangbao ZHANG
Chinese Journal of Integrated Traditional and Western Medicine 2005;25(8):700-703
OBJECTIVETo study the clinical effect of combination of kurarinone (KR) and interferon a-lb (IFNalpha-1b) in treating chronic hepatitis B.
METHODSOne hundred and forty-six patients with chronic hepatitis B were randomized into four groups. Under the basic conventional treatment, additional KR combined IFNa-lb was given to Group A, IFNa-lb to Group B and KR to Group C while none was given to Group D. The therapeutic course for them was 6 months and succeeded with 6 months of follow-up. Changes in liver histology, expression of transforming growth factor beta (TGF-beta) in liver tissue, and serum levels of TGF-beta, hyaluronic acid (HA), laminin (LN), collagen type IV (IVC), precollagen III (PCIII), as well as the negative conversion rate of HBeAg and HBV DNA, and normalization rate of alanine transaminase (ALT) before and after treatment were observed by immuno chemical method, RIA and ELISA.
RESULTSAfter treatment, in Group A, the scores of liver fibrosis and all the above-mentioned indexes significantly lowered, as compared with those in Group B and C, the difference was significant (P<0.05 or P<0.01). The negative conversion rate of TGF-beta in liver tissue was in accordance with the dynamic change of liver fibrosis. Comparison between Group B and C in those aspects showed insignificant difference (P >0.05).
CONCLUSIONKR combined with IFNalpha-1b shows better effect in treating chronic hepatitis B than that of using either of the two alone.
Adult ; DNA, Viral ; blood ; Drug Therapy, Combination ; Drugs, Chinese Herbal ; therapeutic use ; Female ; Flavonoids ; therapeutic use ; Hepatitis B e Antigens ; blood ; Hepatitis B virus ; isolation & purification ; Hepatitis B, Chronic ; drug therapy ; Humans ; Interferon-alpha ; therapeutic use ; Male ; Middle Aged ; Phytotherapy
8.Reconstruction of Ⅴ and Ⅷ bepatic veins in right lobe (without middle hepatic vein) living donor liver transplantation
Mingsheng HUAI ; Zhijun ZHU ; Hong ZHENG ; Yonglin DENG ; Cheng PAN ; Wentao JIANG ; Yamin ZHANG ; Zhongyang SHEN
Chinese Journal of Organ Transplantation 2009;30(6):345-347
Objective To summarize the experience of reconstruction of Ⅴ and Ⅷ hepatic veins in right lobe (without middle hepatic vein) living donor liver transplantation. Methods The clinical data of 55 cases of living donor liver transplantation of right lobe without middle hepatic vein were analyzed, and Ⅴ and Ⅷ hepatic veins were reconstructed. All donors underwent evaluation on the basis of vascular anatomy, GRWR and graft volume/ESLV. Fifty-one grafts underwent reconstruction of Ⅴ and Ⅷ hepatic veins with cold-storage cadaveric iliac veins. Great saphenous vein, varicose umbilical veins, recipient intrahepatic portal veins and recipient intrahepatic veins were used respectively in the remaining 4 cases. Results One recipient died of obstruction of out-flow on the postoperative day 43. One recipient was converted to cadaver donor liver transplantation at the 7th day after operation, because of acute liver function failure. The remaining 53 cases recovered successfully. Conclusion Reconstruction of Ⅴ and Ⅷ hepatic veins with proper materials in right lobe (without middle hepatic vein) living donor liver transplantation is feasible, and the effect is satisfactory.
9.Isotretinoin erythromycin gel in the treatment of acne vulgaris: a multicenter randomized parallel-controlled clinical study
Lunfei LIU ; Jianliang YAN ; Hong FANG ; Hao CHENG ; Weili PAN ; Yingguo DING ; Wei LU ; Min ZHENG
Chinese Journal of Dermatology 2010;43(12):867-870
Objective To compare the clinical efficacy and safety of isotretinoin erythromycin gel, a gel containing isotretinoin (0.05%) and erythromycin (2%), versus adapalene gel in the treatment of mild to moderate acne vulgaris. Methods A multicenter, randomized, open, parallel-controlled clinical study was conducted. A total of 192 patients with mild to moderate (Grade Ⅰ -Ⅲ ) acne vulgaris were enrolled in this study according to the grading criteria for acne severity in guidelines for the treatment of acne in China. Efficacy analysis was carried out in 169 patients and safety analysis in 190 patients. The patients were classified into trial group (n = 86) and control group (n = 83 ) to be treated with isotretinoin erythromycin gel or adapalene gel once a night for 6 weeks. Patients were evaluated at the baseline, on week 2, 4 and 6 during the treatment for the count of comedones (both open and closed), inflammatory papules and pustules, severity of acne and local or general adverse effects. Results After the start of treatment, the response rate gradually increased and severity of acne decreased in both groups. On week 6, the total response rate was 51.16% in the trial group and 40.96% in the control group (P > 0.05), while a greater reduction in the count of pustules and inflammatory lesions was observed on week 4 and 6 in the trial group with a lower severity grade of acne compared with the control group (P < 0.05 or 0.01 ). Adverse reactions were similar in both groups and manifested as tolerable local irritation. Conclusions The efficacy of isotretinoin erythromycin gel is similar to that of adapalene gel in the treatment of mild to moderate acne vulgaris, however, isotretinoin erythromycin gel seems superior to adapalene gel in reducing inflammatory lesions and rapidly improving severity of acne vulgaris.
10.Prognosis of combined liver-kidney transplantation
Liying SUN ; Zhijun ZHU ; Yihe LIU ; Hong ZHENG ; Yonglin DENG ; Cheng PAN ; Zhongyang SHEN
Chinese Journal of Organ Transplantation 2012;33(9):528-530
Objective To analyze the curative effects and survival results of combined liver kidney transplantation (CLKT).Methods From 2002 to 2011,the clinical data of 36 Chinese patients who underwent CLKT were retrospectively analyzed in our centre.The age of recipients was 47.4 ±13.1 years.Four patients had undergone liver transplantation and 7 patients kidney transplantations before CLKT, respectively. The complications and the survival were analyzed. Results The survival patients were followed up for 47.9 months (29.1 - 115.7).The cumulative 1-,3 and 5-year patient survival rate was 88.7%,85.4% and 81.4%; The 1,3- and 5-year survival rate of liver graft was 79.8%,76.3% and 72.3%; The 1-,3- and 5 year survival rate of kidney graft was 85.7%,82.4% and 78.2%.Three patients underwent liver re-transplantation due to severe biliary complications,and one patient kidney re-transplantation due to renal allograft dysfunction.Conclusion CLKT is a effective treatment for end-stage liver disease with renal insufficiency and achieves excellent results.